Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patients

키워드

참고문헌 (49)

1. Vogel A, "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup", Ann Oncol, 29(Suppl 4), pp.iv238~iv255 (2018)
2. Chen LT, "Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced", relapsed hepatocellular carcinoma:a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO, 2020, pp.31, 334~351
3. Kudo M, "A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert consensus statements", Liver Cancer, 9, pp.245~260 (2020)
4. Golfieri R, "Hepatocellular carcinoma responding to superselective transarterial chemoembolization:an issue of nodule dimension?", J Vasc Interv Radiol, 24, pp.509~517 (2013)
5. Peck-Radosavljevic M, "Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis", J Clin Oncol, 36(15 Suppl), pp.4018~ (2018)
6. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)
7. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
8. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
9. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
10. Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial", J Hepatol, 57, pp.821~829 (2012)
11. Yamashita T, "REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset", J Gastroenterol, 55, pp.113~122 (2020)
12. Raoul JL, "How to define transarterial chemoembolization failure or refractoriness: a European perspective", Liver Cancer, 3, pp.119~124 (2014)
13. Bruix J, "Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques", Hepatology, 54, pp.2238~2244 (2011)
14. Kudo M, "Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version", Dig Dis, 29, pp.339~364 (2011)
15. Kudo M, "Transarterial chemoembolization failure", refractoriness: JSH-LCSGJ criteria 2014 update, 2014, pp.87(Suppl 1), 22~31
16. Cheng AL, "Reevaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an international expert panel", Liver Int, 34, pp.174~183 (2014)
17. Surveillance group, "Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan", J Formos Med Assoc, 117, pp.381~403 (2018)
18. Jae Seung Lee, "A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea", Clinical and Molecular Hepatology, 26(1), pp.24~32 (2020), 대한간학회
19. Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
20. Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
21. Sieghart W, "The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 57, pp.2261~2273 (2013)
22. Hucke F, "The ARTstrategy:sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE", J Hepatol, 60, pp.118~126 (2014)
23. Adhoute X, "Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process", J Hepatol, 62, pp.855~862 (2015)
24. Kudo M, "A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE", Liver Cancer, 8, pp.299~311 (2019)
25. Jain RK, "Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy", Science, 307, pp.58~62 (2005)
26. Kano MR, "Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature", Cancer Sci, 100, pp.173~180 (2009)
27. Carmeliet P, "Angiogenesis in cancer and other diseases", Nature, 407, pp.249~257 (2000)
28. Tohyama O, "Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models", J Thyroid Res, 2014, pp.638747~ (2014)
29. Arizumi T, "Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ", Oncology, 87(Suppl 1), pp.32~36 (2014)
30. Lencioni R, "Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC:the SPACE trial", J Hepatol, 64, pp.1090~1098 (2016)
31. Meyer T, "Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial", Lancet Gastroenterol Hepatol, 2, pp.565~575 (2017)
32. Kudo M, "Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial", Gut, 69, pp.1492~1501 (2020)
33. Matsui J, "Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factorreceptor (VEGF-R) 2 and VEGF-R3 kinase", Clin Cancer Res, 14, pp.5459~5465 (2008)
34. Matsui J, "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition", Int J Cancer, 122, pp.664~671 (2008)
35. Yamada K, "Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors", Clin Cancer Res, 17, pp.2528~2537 (2011)
36. Boss DS, "A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours", Br J Cancer, 106, pp.1598~1604 (2012)
37. Kudo M, "Extremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma", Liver Cancer, 7, pp.215~224 (2018)
38. Kudo M, "Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study", Cancers (Basel), 11, pp.1084~ (2019)
39. Kawamura Y, "Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma may be a useful new predictor of early response to lenvatinib and overall prognosis", Liver Cancer, 9, pp.275~292 (2020)
40. Kawamura Y, "18F-fluorodeoxyglucose uptake in hepatocellular carcinoma as a useful predictor of an extremely rapid response to lenvatinib", Liver Cancer, 9, pp.84~92 (2020)
41. Ding X, "Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as firstline treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study", Cancer, 127, pp.3782~3793 (2021)
42. Kudo M, "Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma:a randomized phase III trial", Hepatology, 60, pp.1697~1707 (2014)
43. Kudo M, "Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study", Lancet Gastroenterol Hepatol, 3, pp.37~46 (2018)
44. Yau T, "CheckMate 459:a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR)as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)", Annal Oncol, 30, pp.v874~v875 (2019)
45. Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
46. Duffy AG, "Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma", J Hepatol, 66, pp.545~551 (2017)
47. Chang Y, "Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma", Int J Mol Sci, 21, pp.8165~ (2020)
48. Cheng AL, "IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)", Annal Oncol, 30, pp.ix186~ix187 (2019)
49. Kudo M, "A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma", Hepatobiliary Surg Nutr, 9, pp.530~533 (2020)

관련 논문AI추천